Centessa Pharmaceuticals (UK) Limited

Clinical trials sponsored by Centessa Pharmaceuticals (UK) Limited, explained in plain language.

Now part of Centessa Pharmaceuticals plc CNTA NASDAQ

Develops novel therapies across multiple disease areas.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New sleepiness drug could change lives for narcolepsy and hypersomnia patients Results expected Dec 2026 (estimated)
New drug ORX489 put to the test in healthy adults Results expected Jun 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 5 Terminated 1

Cancer drug study halted early: what we know

Disease control Stopped early

This study tested a new drug called LB101 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drug shrank tumors. The study was terminated early, so results are limited.

Phase 1/2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control

Last updated Jun 27, 2026 07:51 UTC

Centessa Pharmaceuticals (UK) Limited

Upcoming readouts

Cancer drug study halted early: what we know